

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>ROBERTS EIRY</u> (Last) (First) (Middle) 12780 EL CAMINO REAL (Street) SAN DIEGO CA 92130 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>NEUROCRINE BIOSCIENCES INC [NBIX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Medical Officer
	3. Date of Earliest Transaction (Month/Day/Year) 11/08/2024	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/08/2024		M ⁽¹⁾		5,140	A	\$77.81	28,856	D	
Common Stock	11/08/2024		M ⁽¹⁾		1,233	A	\$81.05	30,089	D	
Common Stock	11/08/2024		M ⁽¹⁾		971	A	\$102.9	31,060	D	
Common Stock	11/08/2024		M ⁽¹⁾		1	A	\$79.02	31,061 ⁽²⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Incentive Stock Option	\$77.81	11/08/2024		M			5,140	(3)	01/08/2028	Common Stock	5,140	\$0	0	D	
Incentive Stock Option	\$81.05	11/08/2024		M			1,233	(4)	02/07/2029	Common Stock	1,233	\$0	0	D	
Incentive Stock Option	\$102.9	11/08/2024		M			971	(5)	02/06/2030	Common Stock	971	\$0	0	D	
Incentive Stock Option	\$79.02	11/08/2024		M			1	(6)	01/31/2032	Common Stock	1	\$0	1,265	D	

Explanation of Responses:

- This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
- 29,876 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
- Represents option of which 1/4th of the shares underlying the option became vested and exercisable on January 8, 2019 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
- Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
- Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
- Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Remarks:

/s/ Darin Lippoldt, Attorney-in-Fact 11/12/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.